Wilhelmina Ziekenhuis Assen

Assen 9 trials 5 recruiting

9 Registered trials

5 Currently recruiting

Organisation

Wilhelmina Ziekenhuis Assen

Location

Assen, Netherlands

Identifier

ORG-100047355

Address

Europaweg-Zuid 1, 9401 RK, Netherlands

Departments

Hematology
Internal medicine
Internal medicine/Oncology
Inwendige geneeskunde, interne oncologie
Medical Oncology
Neurology
Oncology
Researchbureau

Clinical trials at this site (9)

Search interface

Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Metastatic Colorectal Cancer 5 2024-10-14
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 low-volume metastatic castration-sensitive prostate can 5 2024-02-02
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Personalized dosing of ocrelizumab in MS Ended

2024-513193-22-00 Multiple Sclerosis 11 2022-03-16
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21